Syngene International Ltd. (SYNGENE) AI Stock Analysis

• Market Cap: ₹262.37B
• Dividend Yield: 0.19%
• Average Volume (3M): 14.30K
• Price to Earnings (P/E): 52.0
• Beta (1Y): 0.78
• Revenue Growth: 7.41%
• EPS Growth: 2.88%
• Country: IN
• Employees: 6,510
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.11
• Shares Outstanding: 402,939,420
• 10 Day Avg. Volume: 18,475
• 30 Day Avg. Volume: 14,298
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹747.50
• Price Target Upside: 13.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 69 Neutral
• Price Target: ₹713.00 ▲(8.30% Upside)

Syngene International Ltd. has a solid financial foundation with strong revenue growth and profitability metrics, which is the most significant factor in its score. Technical indicators suggest some short-term weakness, and valuation metrics indicate the stock may be overvalued. The absence of earnings call data and corporate events limits further insights.

Syngene International Ltd. Business Overview & Revenue Model

Company Description

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

How the Company Makes Money

Syngene International Ltd. generates revenue primarily through its contract research and manufacturing services. The company's business model is based on offering end-to-end solutions to its clients, which include major global pharmaceutical and biotechnology companies. Key revenue streams include fees for research and development services, which involve drug discovery, safety assessment, and clinical development, as well as manufacturing services for small and large molecules. Syngene's strategic partnerships and long-term contracts with leading industry players, such as Bristol-Myers Squibb and Amgen, contribute significantly to its earnings. The company also invests in expanding its capabilities and infrastructure to meet growing demand and enhance service offerings, which further supports revenue growth.

Syngene International Ltd. Financial Statement Overview

Summary

Syngene International Ltd. shows solid financial performance with consistent revenue growth and strong profitability metrics. The balance sheet reflects low leverage and strong asset management. However, there is a need to improve net profit margins and enhance free cash flow retention.

Income Statement

Syngene International Ltd. has demonstrated consistent revenue growth with a revenue growth rate of 4.41% from 2024 to 2025. The gross profit margin is strong at 74.12%, indicating efficient cost management. However, the net profit margin has slightly decreased to 13.62%, which could be a potential area of concern. The EBIT and EBITDA margins are healthy at 16.78% and 31.46%, respectively, showcasing operational efficiency.

Balance Sheet

The company maintains a stable balance sheet with a healthy equity ratio of 69.55%, indicating strong asset backing. The debt-to-equity ratio is low at 0.12, suggesting low leverage and financial stability. Return on equity stands at 10.50%, reflecting solid shareholder returns. Overall, the balance sheet indicates financial health with a cautious approach to debt.

Cash Flow

Syngene International Ltd. has shown a positive free cash flow growth rate, although the rate has decreased due to capital expenditures. The operating cash flow to net income ratio is robust at 2.35, indicating efficient cash generation. The free cash flow to net income ratio is 0.80, suggesting effective capital management, but there is room for improvement in cash retention.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	36.42B	36.42B	34.89B	31.93B	25.07B	20.89B
Gross Profit	20.01B	27.00B	10.32B	23.33B	17.58B	15.63B
EBITDA	11.33B	11.46B	10.85B	9.88B	8.07B	7.67B
Net Income	4.96B	4.96B	5.10B	4.64B	3.96B	4.05B
Balance Sheet
Total Assets	67.96B	67.96B	61.52B	58.31B	55.64B	48.83B
Cash, Cash Equivalents and Short-Term Investments	14.22B	14.22B	10.77B	14.11B	12.81B	10.65B
Total Debt	5.78B	5.78B	5.55B	8.15B	10.22B	8.93B
Total Liabilities	20.69B	20.69B	18.94B	22.13B	22.66B	20.62B
Stockholders Equity	47.27B	47.27B	42.58B	36.18B	32.98B	28.21B
Cash Flow
Free Cash Flow	0.00	3.98B	5.50B	3.05B	1.05B	2.55B
Operating Cash Flow	0.00	11.68B	10.42B	8.38B	5.81B	7.01B
Investing Cash Flow	0.00	-7.45B	-4.96B	-6.88B	-6.12B	-6.28B
Financing Cash Flow	0.00	-1.42B	-5.51B	-3.40B	-313.00M	580.00M

Syngene International Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 658.35
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SYNGENE, the sentiment is Neutral. The current price of 658.35 is above the 20-day moving average (MA) of 652.16, below the 50-day MA of 663.67, and below the 200-day MA of 709.92, indicating a neutral trend. The MACD of -1.09 indicates Negative momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 60.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SYNGENE.

Syngene International Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTERDM	77 Outperform	318.46B	96.91	156.88%	0.81%	-53.19%	-94.01%
SYNGENE	69 Neutral	₹262.37B	51.99		0.19%	7.41%	2.88%
GLAND	69 Neutral	327.51B	42.52	7.63%	0.89%	-2.34%	6.64%
BIOCON	68 Neutral	472.92B	110.57	4.68%	0.14%	6.80%	-75.66%
GLENMARK	54 Neutral	576.25B	76.45	11.83%	0.12%	10.99%	0.00%
LAURUSLABS	54 Neutral	482.33B	94.72	8.01%	0.13%	17.31%	242.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Syngene International Ltd. Corporate Events

Syngene Releases Q1 FY2026 Earnings Call Transcript

Syngene International Limited has announced the availability of the transcript for its Q1 FY2026 earnings call, which took place on July 24, 2025. The transcript is accessible on the company’s website, providing stakeholders with insights into the company’s financial performance and strategic direction for the quarter.

Syngene International Announces AGM and Key Resolutions for 2025

Syngene International Limited has announced its 32nd Annual General Meeting (AGM) scheduled for July 23, 2025, to be held via video conferencing. Key agenda items include the adoption of audited financial statements for the fiscal year ending March 31, 2025, the declaration of a final dividend of Rs. 1.25 per equity share, and the reappointment of Professor Catherine Rosenberg as a director. Additionally, the company plans to appoint M/s V Sreedharan & Associates as secretarial auditors and recommend Ms. Vinita Bali as a Non-Executive Director. These decisions are poised to impact the company’s governance and financial distribution strategy, reflecting its commitment to shareholder engagement and corporate compliance.